The population is invisible
For many rare diseases, most of the addressable population has no diagnosis yet. The patients exist; the diagnosis codes do not.
For life sciences
The patients your program needs are already in the data.
Undiagnosed patients are the bottleneck for a rare disease franchise: for the trial, for the launch, for the therapy itself. PathfindEHR™ helps partner health systems surface those patients from data they already hold, so specialists can review them and act.
The problem
Why rare disease programs stall.
Enrollment windows slip
Trials and early-access programs stall when eligible patients cannot be found, and every month of delay costs the program.
Lists you cannot defend
A vendor list of likely patients with no visible reasoning is hard to put in front of a clinician, a compliance team, or a regulator.
How it works
Your program, their data, a clear boundary.
You bring the disease area. A partner health system brings its existing FHIR and real-world data. We bring the governed pathway: a definition of the disease curated and signed off by key opinion leaders, applied in place, inside the health system’s environment.
The health system’s specialists review the surfaced candidates and the evidence behind each one. Protected health information never crosses the boundary to you. We wrote about why that structure works in Patient finding is a partnership.
What you get: a reproducible, defensible patient-finding capability in partner systems, with program-level visibility into how it is performing.
What you never touch: patient records. Candidates, evidence, and clinical decisions stay with the treating system and its clinicians.
Ways to work together
From a single pilot to a multi-year program.
Strategic patient-finding programs
Multi-year collaborations where we jointly define disease pathways, run recurring patient-finding on your EHR/RWD, and measure downstream impact on diagnosis, trial enrollment, and therapy uptake.
Targeted pilots and proof-of-concept
Narrowly scoped pilots focused on a single disease or franchise, designed to de-risk integration, validate yield and lift, and build the internal case for broader deployment.
Embedded expertise and advisory
Access to our diagnostic strategy team for pathway refinement, trial design support, indication expansion, and evidence-generation planning — with PathfindEHR™ cohorts as the starting point, not the endpoint.
FAQ
What life sciences teams ask us.
How does patient finding support a rare disease franchise?
A therapy can only reach patients after specialists find and diagnose them. PathfindEHR™ applies a governed, KOL-approved definition of your disease area to a partner health system’s existing data and surfaces candidates, with evidence, for that system’s specialists to review. The downstream effects show up where you measure them: diagnosis, trial enrollment, and appropriate treatment.
Do we receive patient-level data?
No. Analysis runs inside the health system’s governed environment and protected health information stays there. Your team sees how the program is performing, not who the patients are.
Can this help with clinical trial enrollment?
Yes, as decision support for the clinicians involved. Governed pathways can be scoped to trial-relevant criteria, so specialists at partner sites can review candidates who may warrant evaluation. Investigators and treating clinicians make every enrollment and referral decision.
What does a first engagement look like?
A first engagement is designed as a narrowly scoped pilot: one disease or franchise, one partner data environment, and success measures agreed up front, so the case for a broader program rests on results rather than promises.
Tell us about your disease area.
We’ll walk you through what a governed patient-finding pilot would look like for your program.